By: Adam Feuerstein | 06/02/14 - 03:20 PM EDT
It's me again, still reporting from the American Society of Clinical Oncology (ASCO) annual meeting. We just got our first look at the clinical activity of
(INCY) immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with
(BMY) Yervoy in melanoma patients. The Wall Street scrum around the Incyte poster was insane.
$INCY IDO poster scrum. #ASCO14 pic.twitter.com/yAk04mYGJ5 Adam Feuerstein (@adamfeuerstein) June 2, 2014Oh yeah, you're probably interesting in hearing about the data. Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response rate of 50%. A third patient reported stable disease so the disease control rate was 75%. The Incyte press release and poster can be found here.
12/19/14 - 04:16 PM EST
12/19/14 - 08:25 AM EST
12/16/14 - 11:20 AM EST
12/15/14 - 09:23 AM EST
12/03/14 - 04:01 PM EST
12/27/14 - 15:04 PM EST
12/26/14 - 09:49 AM EST
12/24/14 - 08:45 AM EST
12/23/14 - 10:03 AM EST
12/23/14 - 06:07 AM EST
Access the tool that DOMINATES the Russell 2000 and the S&P 500.